Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide for Liver Recovery After Major Hepatectomy
NCT03179995Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Jul 2017
- Primary completion
- Feb 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of Octreotide long-acting injection in post-hepatectomy liver failure (PHLF), sponsored by Fox Chase Cancer Center. Started Jul 2017; status: terminated.
02
Drugs
Octreotide long-acting injection
03
Conditions
post-hepatectomy liver failure (PHLF)
Beyond the preview
Go deeper on NCT03179995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03179995.